Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

BACKGROUND. Prodrug-activator gene therapy with Toca 511, a tumor-selective retroviral replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent high-grade glioma patients. Nonlytic retroviral infection leads to permanent integration of RRV into the cancer cell geno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiraoka, Kei, Inagaki, Akihito, Kato, Yuki, Huang, Tiffany T., Mitchell, Leah A., Kamijima, Shuichi, Takahashi, Masamichi, Matsumoto, Hiroshi, Hacke, Katrin, Kruse, Carol A., Ostertag, Derek, Robbins, Joan M., Gruber, Harry E., Jolly, Douglas J., Kasahara, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574670/
https://www.ncbi.nlm.nih.gov/pubmed/28387831
http://dx.doi.org/10.1093/neuonc/nox038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574670/
https://www.ncbi.nlm.nih.gov/pubmed/28387831
http://dx.doi.org/10.1093/neuonc/nox038

Ejemplares similares